The World Health Organization (WHO) has named three Coronavirus vaccine candidates developed by Bangladeshi vaccine company Globe Biotech Ltd on its “draft landscape of COVID-19 candidate vaccines”.
The WHO listed Globe’s vaccine on its draft landscape of Covid-19 candidate vaccines on 15 October.
The Globe Biotech Limited on its website confirmed the WHO’s acknowledgment of listing the Coronavirus vaccines.
The organization has updated Globe Biotech’s three candidate vaccines in preclinical evaluation — DNA plasmid vaccine, Adenovirus Type 5 Vector, and D614G variant LNP-encapsulated mRNA — on its “Draft landscape of COVID-19 candidate vaccines”, updated on 15 October 2020.
Previously, American Medical Journal Bioarchive published a report on vaccines produced by Globe Biotech on September 30.
With WHO’s acknowledgment, the pharmaceutical company has entered the global race for the Coronavirus vaccine as a first-ever Bangladeshi company.
However, this doesn’t guarantee the vaccine’s effectiveness or success, according to the experts.
Globe Biotech on July 2 announced that it began developing a Covid-19 vaccine named — BANCOVID.
On October 5, the company revealed that Bangladesh Medical Research Council cleared the last requirement for the firm to seek ethical approval for the vaccine’s human trial.
The biotech firm hoped that “BANCOVID” will hit the market by mid-February, 2021.